This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Nov;82(11):1316-8.

doi: 10.4065/82.11.1316.

Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?

PMID: 17976350
DOI: 10.4065/82.11.1316

Editorial

Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?

Ayalew Tefferi. Mayo Clin Proc. 2007 Nov.

. 2007 Nov;82(11):1316-8.

doi: 10.4065/82.11.1316.

Author

PMID: 17976350
DOI: 10.4065/82.11.1316

No abstract available

PubMed Disclaimer

Comment on

Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
Wish JB, Coyne DW. Wish JB, et al. Mayo Clin Proc. 2007 Nov;82(11):1371-80. doi: 10.4065/82.11.1371. Mayo Clin Proc. 2007. PMID: 17976358 Review.

Similar articles

Erythropoietin use in CKD patients with cancer: to tread with caution?
Nayak-Rao S, McCormick B. Nayak-Rao S, et al. J Nephrol. 2013 Sep-Oct;26(5):829-35. doi: 10.5301/jn.5000316. Epub 2013 Sep 18. J Nephrol. 2013. PMID: 24052463 Review.
Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR, Dunst J, Vaupel P. Nowrousian MR, et al. Strahlenther Onkol. 2008 Mar;184(3):121-36. doi: 10.1007/s00066-008-1841-3. Strahlenther Onkol. 2008. PMID: 18330508 Review.
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
Bennett CL, Lai SY, Sartor O, Georgantopoulos P, Hrushesky WJ, Henke M, Armitage JO. Bennett CL, et al. JAMA Oncol. 2016 Jan;2(1):134-6. doi: 10.1001/jamaoncol.2015.3940. JAMA Oncol. 2016. PMID: 26606114 Review. No abstract available.
Erythropoietin: high profile, high scrutiny.
Crawford J. Crawford J. J Clin Oncol. 2007 Mar 20;25(9):1021-3. doi: 10.1200/JCO.2006.08.8153. Epub 2007 Feb 20. J Clin Oncol. 2007. PMID: 17312331 No abstract available.
Erythropoietin and radiotherapy: a dangerous combination?
Dunst J. Dunst J. Strahlenther Onkol. 2004 Mar;180(3):133-5. Strahlenther Onkol. 2004. PMID: 15032246 No abstract available.

See all similar articles

Cited by

Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.
Curran MP, McCormack PL. Curran MP, et al. Drugs. 2008;68(8):1139-56. doi: 10.2165/00003495-200868080-00009. Drugs. 2008. PMID: 18484803 Review.
Therapeutic developments in Friedreich ataxia.
Wilson RB. Wilson RB. J Child Neurol. 2012 Sep;27(9):1212-6. doi: 10.1177/0883073812449691. Epub 2012 Jul 12. J Child Neurol. 2012. PMID: 22791549 Free PMC article. Review.
Pharmacotherapy for Friedreich ataxia.
Tsou AY, Friedman LS, Wilson RB, Lynch DR. Tsou AY, et al. CNS Drugs. 2009;23(3):213-23. doi: 10.2165/00023210-200923030-00003. CNS Drugs. 2009. PMID: 19320530 Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information